VXRT Vaxart, Inc.

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.

Company profile

Ticker

VXRT

Exchange

NASDAQ

Website

www.vaxart.com

CEO

Wouter W. Latour

Incorporated in

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Health Technology > Biotechnology

Industry (SEC)

Biological Products, (No Diagnostic Substances)

Amgen • Gilead Sciences • Biogen • Qiagen • Bio-Techne • Moderna • Acorda Therapeutics • PDL BioPharma • BioNTech SE • bluebird bio ...

Former names

Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., Nabi Biopharmaceuticals, Nabi, Nabi Biopharmaceuticals, North American Biologicals Inc

SEC CIK

0000072444

Corporate docs

Articles of Incorporation & Bylaws

IRS number

591212264

VXRT stock data

S&P 500

1M 1Y 2Y 5Y

FINRA relative short interest over last month (20 trading days) ?

Company financial data Financial data

Chart VXRT financial data

Quarter (USD)	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	3.92M	454K	85K	5.41M
Net income	-6.41M	-5.26M	-5.64M	-1.34M
Diluted EPS	-0.13	-0.32	-0.39	-0.18
Net profit margin	-164%	-1159%	-6632%	-24.76%
Operating income	-5.63M	-4.71M	-5M	-448K
Net change in cash	-6.03M	3.3M	7.88M	-3.08M
Cash on hand	13.51M	19.54M	16.24M	8.36M
Cost of revenue

Annual (USD)	Dec 19	Dec 18	Dec 17
Revenue	9.86M	4.16M	5.84M
Net income	-18.65M	-18.01M	-9.58M
Diluted EPS	-0.86	-2.9	-91.65
Net profit margin	-189%	-433%	-164%
Operating income	-15.79M	-21.76M	-10.02M
Net change in cash	2.07M	9.87M
Cash on hand	13.51M	11.44M	1.57M
Cost of revenue

Financial data from Vaxart earnings reports

Recent insider trades

VXRT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	$Price	#Shares	$Value	#Remaining
18 Nov 19	Robert A. Yedid	Stock Option Common Stock	Grant	Aquire A	0.31	54,720	16.96K	54,720
18 Nov 19	Todd C Davis	Stock Option Common Stock	Grant	Aquire A	0.31	54,720	16.96K	54,720
7 Nov 19	Armistice Capital	Common Stock	Buy	Aquire P	0	0	0	25,200,000
7 Nov 19	Armistice Capital	Common Stock	Buy	Aquire P	0.34	63,749	21.67K	25,200,000
6 Nov 19	Armistice Capital	Common Stock	Buy	Aquire P	0	0	0	25,136,251
6 Nov 19	Armistice Capital	Common Stock	Buy	Aquire P	0.34	61,869	21.04K	25,136,251
5 Nov 19	Armistice Capital	Common Stock	Buy	Aquire P	0	0	0	25,074,382
5 Nov 19	Armistice Capital	Common Stock	Buy	Aquire P	0.33	74,382	24.55K	25,074,382

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2019

VXRT institutional ownership history Ownership history

37.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	20	20	–
Opened positions	3	5	-40.0%
Closed positions	3	4	-25.0%
Increased positions	4	3	+33.3%
Reduced positions	2	3	-33.3%

13F shares	Current	Prev Q	Change
Total value	12.91M	13.12M	-1.6%
Total shares	26.82M	26.56M	+1.0%
Total puts	0	0	–
Total calls	0	0	–
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Armistice Capital	25.2M	$8.83M	+5.0%
Renaissance Technologies	1.37M	$480K	+41.8%
UBS UBS	62.72K	$22K	-41.7%
Geode Capital Management	44.73K	$15K	0.0%
BLK BlackRock	40.41K	$15K	0.0%
Vanguard	33.22K	$12K	0.0%
Carlson Capital Management	28.45K	$10K	0.0%
DB Deutsche Bank	10.84K	$3K	NEW
Parallel Advisors	10.4K	$4K	+50.7%
RPg Family Wealth Advisory	10K	$3.51M	0.0%

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	25.2M	+1.2M	+5.0%
Sabby Management	0	-1.2M	EXIT
Renaissance Technologies	1.37M	+403.82K	+41.8%
Citadel Advisors	0	-86.22K	EXIT
UBS UBS	62.72K	-44.88K	-41.7%
VIRT Virtu Financial	0	-27.97K	EXIT
DB Deutsche Bank	10.84K	+10.84K	NEW
Victory Capital Management	7.95K	+5.78K	+267.1%
Parallel Advisors	10.4K	+3.5K	+50.7%
IFP Advisors	0	-162	EXIT

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accredited, aerosolized, ahead, Armistice, arose, bear, borne, broker, campaign, ceiling, China, coincide, compliment, Concept, confront, disappointing, divest, dot, downturn, elder, encompassing, endeavor, Equine, estate, expiry, fourfold, Fundamental, grace, Gravidarum, HBGA, hedge, immunogenecity, ImmunoTech, implicit, incorrectly, incurrence, intensified, IRS, Janssen, malaise, marginal, Master, Moderna, mortgage, Myalgia, nonroutine, orange, OUM, partnership, penny, permanent, placement, PP, Proof, purple, ready, repaid, residence, revert, RIAA, robert, rolling, RPO, runway, sentinel, shareholder, speculative, spread, stepdown, surpassed, tabulated, TEAE, todd, topline, Trump, unbilled, underwritten, unexercised, unpartnered, Venezuelan, worth, wrote, Wuhan, yedid

Removed: accelerated, acquirer, amendment, American, August, AVIR, award, Biota, calculating, capsid, Carlo, chemical, circumvented, Colonnese, compensatory, comprised, compulsory, condyloma, consisted, continuation, cox, denied, description, disposition, disseminate, Dunne, expiring, function, fusion, geoffrey, GLP, incorporation, Joseph, Mark, mature, meal, Monte, nabi, NI, Patti, preceding, principle, prospectively, reject, remeasurement, restated, richard, Russell, SA, salary, scaling, simulation, sponsored, street, sum, taxable, upper, vapendavir, vice, website, withdrawn

From filing 10-K 2019 FY